MK 6349Alternative Names: MK6349
Latest Information Update: 27 Jul 2009
At a glance
- Originator Merck & Co
- Class Antihyperglycaemics
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 21 Jul 2009 Discontinued - Phase-I for Type-2 diabetes mellitus in USA (unspecified route)
- 31 May 2007 Phase-I clinical trials in Type-2 diabetes mellitus in USA (unspecified route)